ArticleTranslational lung cancer research2025
International cost-effectiveness analysis of nivolumab plus ipilimumab-based for metastatic non-small cell lung cancer with PD-L1 lower than 1.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dual immunotherapy has demonstrated efficacy in treating non-small cell lung cancer (NSCLC) with tumor programmed cell death ligand 1 (PD-L1) lower than 1%. However, its widespread clinical implementation has been hindered by high costs, necessitating cost-effectiveness evaluations in the context of national healthcare payers. This study aims to evaluate the cost and clinical effect of nivolumab plus ipilimumab versus chemotherapy for NSCLC with PD-L1 lower than 1% from the perspective of payers in the USA and China. Methods: The CheckMate 227 and CheckMate 9LA trials were leveraged to devise a three-state Markov model using pooled data to simulate the disease trajectory in NSCLC with PD-L1 lower than 1%. The model assessed the lifetime total costs, incremental cost-effectiveness ratios (ICERs), and incremental net health benefit (INHB) of nivolumab plus ipilimumab versus chemotherapy in the contexts of American and Chinese payers. The respective willingness-to-pay (WTP) thresholds were set at $100,000 and $36,255 per quality-adjusted life-year (QALY). Sensitivity and subgroup analyses were performed to assess the robustness of the model. Results: Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. However, this regimen was related to significantly higher total costs ($262,974 versus $146,772 in the USA and $43,217 versus $15,269 in China), yielding ICERs of $104,126/QALY and $29,143/QALY in the USA and in China, respectively. Among various influencing factors, patient body weight emerged as the most significant determinant. Subgroup analyses suggested that patients with brain metastases and squamous carcinoma were associated with greater benefits from the dual-immunotherapy approach. Conclusions: First-line nivolumab plus ipilimumab was deemed cost-effective for metastatic NSCLC with PD-L1 lower than 1% in China but did not meet cost-effectiveness in the USA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.